1
|
Sozarukova MM, Proskurnina EV, Popov AL, Kalinkin AL, Ivanov VK. New facets of nanozyme activity of ceria: lipo- and phospholipoperoxidase-like behaviour of CeO 2 nanoparticles. RSC Adv 2021; 11:35351-35360. [PMID: 35493182 PMCID: PMC9043017 DOI: 10.1039/d1ra06730c] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2021] [Accepted: 10/22/2021] [Indexed: 12/23/2022] Open
Abstract
Cerium dioxide nanoparticles have a special place among engineered nanomaterials due to the wide range of their enzyme-like activities. They possess SOD-, catalase- and peroxidase-like properties, as well as recently discovered phosphatase-, photolyase-, phospholipase- and nuclease-like properties. Advancing biomedical applications of CeO2-based nanozymes requires an understanding of the features and mechanisms of the redox activity of CeO2 nanoparticles when entering the vascular bed, especially when interacting with lipid-protein supramolecular complexes (biomembranes and lipoproteins). In this paper, CeO2 nanoparticles are shown to possess two further types of nanozyme activity, namely lipo- and phospholipoperoxidase-like activities. Compared to a strong blood prooxidant, hemoglobin, CeO2 nanoparticles act as a mild oxidising agent, since they exhibit a 106 times lower, and 20 times lower, prooxidant capacity towards linoleic acid and phosphatidylcholine hydroperoxides, respectively. Compared to the widespread pharmacological preparation of iron, Fe(iii) carboxymaltose (antianemic preparation Ferinject®), the prooxidant capacity of CeO2 nanoparticles towards lipid and phospholipid substrates has been shown to be 102 times lower, and 4 times higher, respectively. The data obtained on the mechanism of the interaction of nanodisperse CeO2 with the main components of biological membranes, lipids and phospholipids enable the substantial expansion of the scope of biomedical applications of CeO2 nanozymes. CeO2 nanoparticles were shown to possess two novel types of enzyme-like activity, namely lipoperoxidase and phospholipoperoxidase activity.![]()
Collapse
Affiliation(s)
- Madina M Sozarukova
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences Russian Federation
| | | | - Anton L Popov
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences Russian Federation .,Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences Russian Federation
| | - Alexander L Kalinkin
- Medical Research and Educational Center, Lomonosov Moscow State University Russian Federation
| | - Vladimir K Ivanov
- Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences Russian Federation .,National Research University Higher School of Economics Russian Federation
| |
Collapse
|
2
|
Gusev EI, Blokhin VE, Vartanov SA, Martynov MY, Katunina EA, Alesenko AV, Denisova IA, Pavlova EN, Polterovich VM, Kucheryanu VG, Shupik MA, Nodel MR, Kalinkin AL, Sokolov SA, Chubarova TV, Shakleina MV, Pronina TS, Ugryumov MV. [Development of early diagnosis of Parkinson's disease and comprehensive economic analysis of the effect of its implementation]. Zh Nevrol Psikhiatr Im S S Korsakova 2021; 121:9-20. [PMID: 33580755 DOI: 10.17116/jnevro20211210119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The paper summarizes the literature and author's data on the development of early (preclinical) diagnosis of Parkinson's disease (PD). Implementation of this diagnosis will promote the use of preventive therapy and change investments in diagnosis and treatment of patients. The paper declares that at present the only approach to early diagnosis of PD is positron-emission tomography of the nigrostriatal dopaminergic system, but it cannot be used for preventive examination due to its high cost. The authors consider that a less specific, but more promising approach to the development of early diagnosis of PD is the search for markers in body fluids, mainly in the blood, in patients at the prodromal stage of PD. Indeed, a number of markers as changes in the level of metabolites of monoamines, sphingolipids, urates, and indicators of oxidative stress were found in patients selected for the risk group of the prodromal stage of PD, according to characteristic premotor symptoms. In addition, it is assumed that the search for blood markers at an earlier - pre-prodromal stage is possible only in animal models of PD at the early preclinical stage. This approach can also be used to verify blood markers identified in patients at the clinical stage of PD. It is also evident that the complex socio-economic factors influencing the incidence of PD is different in developed versus developing countries. The societal and medical costs of Parkinson's are huge and efforts to improve early preclinical diagnosis of PD will lead to considerable economical and societal benefits. For instance this will allow efficient selection of patients for preclinical diagnostic tests. To assess the effectiveness of this strategy considering the uncertainty of socio-economic issues, a modification of the «cost-utility» analysis is proposed. For the first time, a Markov model of PD including preclinical diagnostic tests and possible neuroprotective therapy was developed and studied. Analytical outcomes of this process suggest that the idea of developing a new multimodal strategy is promising from a socio-economic point of view.
Collapse
Affiliation(s)
- E I Gusev
- Pirogov Russian National Research Medical University, Moscow, Russia
| | - V E Blokhin
- Koltsov Institute of Developmental Biology of the Russian Academy of Sciences, Moscow, Russia
| | - S A Vartanov
- Moscow School of Economics of the Lomonosov Moscow State University, Moscow, Russia
| | - M Yu Martynov
- Pirogov Russian National Research Medical University, Moscow, Russia
| | - E A Katunina
- Pirogov Russian National Research Medical University, Moscow, Russia.,Federal Center for Brain and Neurotechnology, Moscow, Russia
| | - A V Alesenko
- Emanuel Institute of Biochemical Physics of the Russian Academy of Sciences, Moscow, Russia
| | - I A Denisova
- Moscow School of Economics of the Lomonosov Moscow State University, Moscow, Russia
| | - E N Pavlova
- Koltsov Institute of Developmental Biology of the Russian Academy of Sciences, Moscow, Russia
| | - V M Polterovich
- Moscow School of Economics of the Lomonosov Moscow State University, Moscow, Russia.,Central Economic and Mathematical Institute of the Russian Academy of Sciences, Moscow, Russia
| | - V G Kucheryanu
- Research Institute of General Pathology and Pathophysiology, Moscow, Russia
| | - M A Shupik
- Emanuel Institute of Biochemical Physics of the Russian Academy of Sciences, Moscow, Russia
| | - M R Nodel
- Sechenov First Moscow State Medical University, Moscow, Russia
| | - A L Kalinkin
- Medical Research and Education Center of the Lomonosov Moscow State University, Moscow, Russia
| | - S A Sokolov
- Medical Research and Education Center of the Lomonosov Moscow State University, Moscow, Russia
| | - T V Chubarova
- Institute of Economics of the Russian Academy of Sciences, Moscow, Russia
| | - M V Shakleina
- Moscow School of Economics of the Lomonosov Moscow State University, Moscow, Russia
| | - T S Pronina
- Koltsov Institute of Developmental Biology of the Russian Academy of Sciences, Moscow, Russia
| | - M V Ugryumov
- Koltsov Institute of Developmental Biology of the Russian Academy of Sciences, Moscow, Russia
| |
Collapse
|
3
|
Gusev EI, Katunina EA, Martinov MY, Blokhin VE, Kalinkin AL, Alesenko AV, Nodel MR, Malykhina EA, Titova NV, Katunin DA, Shupik MA, Gutner UA, Maloshitskaya OA, Sokolov SA, Kucheryanu VG, Pavlova EN, Ugrumov MV. [Development of early diagnosis of Parkinson's disease based on the search for biomarkers such as premotor symptoms and changes in blood]. Zh Nevrol Psikhiatr Im S S Korsakova 2021; 120:7-17. [PMID: 33459535 DOI: 10.17116/jnevro20201201217] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVE To determine changes in the chemical composition of blood plasma in subjects at risk of Parkinson's disease (PD) at the prodromal stage compared with age control. MATERIAL AND METHODS Subjects at risk were selected for the presence of characteristic premotor symptoms, including impairments of sleep, olfaction and constipation.The risk group included 12 people, the control group - 8 people. RESULTS Among seven catecholamines and their metabolites detected in the blood, only the concentration of L-dioxiphenylalanine (L-DOPA) changed (decreased) in subjects at risk compared with the control. A decrease in the concentration of L-DOPA is considered as a manifestation (marker) of selective degeneration of central and peripheral catecholaminergic neurons in PD. In contrast to L-DOPA, the concentration of seven of the twelve detected sphingomyelins in the blood of the subjects at risk increased. Given that a change in the metabolism of sphingomyelins is associated with processes such as apoptosis, autophagy, and synucleinopathy, an increase in their concentration in the blood of patients at risk is considered as a manifestation of systemic general degeneration of central and peripheral neurons. Finally, in the blood of subjects at risk, we found a trend towards a decrease in the concentration of urates, which are endogenous neuroprotectors. CONCLUSION The changes in the level of L-DOPA, sphingmyelins and urates in the blood of subjects at risk may serve as diagnostic markers of PD at the prodromal stage.
Collapse
Affiliation(s)
- E I Gusev
- Pirogov Russian National Research Medical University, Moscow, Russia
| | - E A Katunina
- Pirogov Russian National Research Medical University, Moscow, Russia.,Federal Center for Brain and Neurotechnologies, Moscow, Russia
| | - M Yu Martinov
- Pirogov Russian National Research Medical University, Moscow, Russia
| | - V E Blokhin
- Koltsov Institute of Developmental Biology RAS, Moscow, Russia
| | - A L Kalinkin
- Medical Research and Education Center of Lomonosov Moscow State University, Moscow, Russia
| | - A V Alesenko
- Emanuel Institute of Biochemical Physics RAS, Moscow, Russia
| | - M R Nodel
- Sechenov First Moscow State Medical University, Moscow, Russia
| | - E A Malykhina
- Pirogov Russian National Research Medical University, Moscow, Russia.,Federal Center for Brain and Neurotechnologies, Moscow, Russia
| | - N V Titova
- Pirogov Russian National Research Medical University, Moscow, Russia.,Federal Center for Brain and Neurotechnologies, Moscow, Russia
| | - D A Katunin
- Pirogov Russian National Research Medical University, Moscow, Russia.,Federal Center for Brain and Neurotechnologies, Moscow, Russia
| | - M A Shupik
- Emanuel Institute of Biochemical Physics RAS, Moscow, Russia
| | - U A Gutner
- Emanuel Institute of Biochemical Physics RAS, Moscow, Russia
| | | | - S A Sokolov
- Lomonosov Moscow State University, Moscow, Russia
| | - V G Kucheryanu
- Institute of General Pathology and Pathophysiology, Moscow, Russia
| | - E N Pavlova
- Koltsov Institute of Developmental Biology RAS, Moscow, Russia
| | - M V Ugrumov
- Koltsov Institute of Developmental Biology RAS, Moscow, Russia
| |
Collapse
|
4
|
Mareev VY, Orlova YA, Pavlikova EP, Matskeplishvili ST, Krasnova TN, Malahov PS, Samokhodskaya LM, Mershina EA, Sinitsyn VE, Mareev YV, Kalinkin AL, Begrambekova YL, Kamalov AA. [Steroid pulse -therapy in patients With coronAvirus Pneumonia (COVID-19), sYstemic inFlammation And Risk of vEnous thRombosis and thromboembolism (WAYFARER Study)]. ACTA ACUST UNITED AC 2020; 60:15-29. [PMID: 32720612 DOI: 10.18087/cardio.2020.6.n1226] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2020] [Accepted: 06/18/2020] [Indexed: 01/29/2023]
Abstract
Introduction Coronavirus pneumonia not only severely affects the lung tissue but is also associated with systemic autoimmune inflammation, rapid overactivation of cytokines and chemokines known as "cytokine storm", and a high risk of thrombosis and thromboembolism. Since there is no specific therapy for this new coronavirus infection (COVID-19), searching for an effective and safe anti-inflammatory therapy is critical.Materials and methods This study evaluated efficacy and safety of pulse therapy with high doses of glucocorticosteroids (GCS), methylprednisolone 1,000 mg for 3 days plus dexamethasone 8 mg for another 3-5 days, in 17 patients with severe coronavirus pneumonia as a part of retrospective comparative analysis (17 patients in control group). The study primary endpoint was the aggregate dynamics of patients' condition as evaluated by an original CCS-COVID scale, which included, in addition to the clinical status, assessments of changes in the inflammation marker, C-reactive protein (CRP); the thrombus formation marker, D-dimer; and the extent of lung injury evaluated by computed tomography (CT). Patients had signs of lung injury (53.2 % and 25.6 %), increases in CRP 27 and 19 times, and a more than doubled level of D-dimer (to 1.41 µg/ml and 1.15 µg/ml) in the active therapy and the control groups, respectively. The GCS treatment group had a more severe condition at baseline.Results The GCS pulse therapy proved effective and significantly decreased the CCS-COVID scores. Median score difference was 5.00 compared to the control group (р=0.011). Shortness of breath considerably decreased; oxygen saturation increased, and the NEWS-2 clinical status scale scores decreased. In the GCS group, concentration of CRP significantly decreased from 134 mg/dl to 41.8 mg/dl (р=0.009) but at the same time, D-dimer level significantly increased from 1.41 µg/ml to 1.98 µg/ml (р=0.044). In the control group, the changes were nonsignificant. The dynamics of lung injury by CT was better in the treatment group but the difference did not reach a statistical significance (р=0.062). Following the GCS treatment, neutrophilia increased (р=0.0001) with persisting lymphopenia, and the neutrophil/lymphocyte (N/L) ratio, a marker of chronic inflammation, increased 2.5 times (р=0.006). The changes in the N/L ratio and D-dimer were found to correlate in the GCS pulse therapy group (r =0.49, p=0.04), which underlined the relationship of chronic autoimmune inflammation with thrombus formation in COVID-19. No significant changes were observed in the control group. In result, four patients developed venous thromboembolic complications (two of them had pulmonary artery thromboembolism) after the GCS pulse therapy despite the concomitant antiplatelet treatment at therapeutic doses. Recovery was slower in the hormone treatment group (median stay in the hospital was 26 days vs 18 days in the control group, р=0.001).Conclusion Pulse therapy with high doses of GCS exerted a rapid anti-inflammatory effect but at the same time, increased the N/L ratio and the D-dimer level, which increased the risk of thromboembolism.
Collapse
Affiliation(s)
- V Yu Mareev
- Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia
| | - Ya A Orlova
- Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia
| | - E P Pavlikova
- Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia
| | - S T Matskeplishvili
- Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia
| | - T N Krasnova
- Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia
| | - P S Malahov
- Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia
| | - L M Samokhodskaya
- Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia
| | - E A Mershina
- Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia
| | - V E Sinitsyn
- Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia
| | - Yu V Mareev
- National Medical Research Centre for Therapy and Preventive Medicine, Moscow, Russia Robertson Centre for Biostatistics. University of Glasgow
| | - A L Kalinkin
- Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia
| | - Yu L Begrambekova
- Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia
| | - A A Kamalov
- Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia
| |
Collapse
|
5
|
Kovalzon VM, Ugrumov MV, Pronina TS, Dorokhov VB, Manolov AI, Dolgikh VV, Ukraintseva YV, Moiseenko LS, Poluektov MG, Kalinkin AL. [Early Stages of Parkinson's Disease: Comparative Characteristics of Sleep-Wakefulness Cycle in Patients and Model Animals]. Fiziol Cheloveka 2015; 41:114-118. [PMID: 26859995] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
The results of study of sleep-wakefulness cycle in experimental models of pre-clinical and early clinical stages of Parkinson's disease present and compared to some clinical examples. The conclusion is, the increase in activity level and decrease in total amount of slow wave and paradoxical sleep in model animals are taking place at the same circadian period of the secretion of pineal melatonin as sleep disorders in patients.
Collapse
|
6
|
Eroshina EV, Kalinkin AL, Sidorenko BA. [The diagnostic efficiency of the methods of separate and combined registration of oronasal airflow and pulse oximetry for detection of the obstructive sleep apnea/hypopnea syndrome]. Kardiologiia 2013; 53:77-82. [PMID: 24090391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
The diagnostic efficiency of the methods of separate and combined registration of oronasal airflow and pulse oximetry in order to identify the obstructive sleep apnea/hypopnea syndrome (OSAHS) is studied in this work. Patients with cardiovascular diseases with complaints on sleep disorders were included in the study. Combined registration of oronasal airflow and pulse oximetry during sleep were performed for all examined patients (diagnostic system ApneaLink with pulse oximetry, ResMed). Registration results of oronasal airflow and pulse oximetry were analyzed separately and together. Apnea/hypopnea index (classic, recommended), desaturation index with a threshold of desaturation of 4% and 3% were evaluated as the diagnostic criteria for the identification of OSAHS. Also, in this paper the "apnea/hypopnea combined index" summarizing hypopnea episodes, which are associated with significant desaturation and without desaturation, was tested. As a method of comparison, polysomnography (Embla N7000, MedCare Flaga), which was carried out simultaneously with the main study, was used. The diagnostic efficiency of test methods and their criteria assessed by ROC-analysis (receiver operator characteristic, the characteristic curve analysis). The results of the study showed that combined registration of respiratory oronasal airflow and pulse oximetry during sleep was most effectively identified OSAHS and can be used as a screening method. The most accurate diagnostic criterion for identification of OSAHS is an "apnea/hypopnea combined index".
Collapse
Affiliation(s)
- E V Eroshina
- Educational Scientific Medical Centre of the General Management Department of the President of RF, ul. Marshala Timoshenko 21, 121359 Moscow, Russia
| | | | | |
Collapse
|
7
|
Korostovtseva LS, Sviryaev YV, Zvartau NE, Konradi AO, Kalinkin AL. Prognosis and cardiovascular morbidity and mortality in prospective study of hypertensive patients with obstructive sleep apnea syndrome in St Petersburg, Russia. Med Sci Monit 2011; 17:CR146-53. [PMID: 21358601 PMCID: PMC3524738 DOI: 10.12659/msm.881448] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2010] [Accepted: 10/13/2010] [Indexed: 12/05/2022] Open
Abstract
BACKGROUND To assess the impact of obstructive sleep apnea-hypopnea syndrome (OSAHS) on prognosis and cardiovascular morbidity and mortality in relation to other major cardiovascular risk factors. MATERIAL/METHODS This prospective study recruited 234 patients from an out-patient clinic. Based on the Berlin questionnaire, 147 patients (90 males, mean age 52.1 ± 10.4 years) with highly suspected sleep breathing disorders were included in the study. Based on cardiorespiratory monitoring, patients were divided into 2 groups: 42 patients without sleep breathing disorders (SBD), and 105 patients with OSAHS. Among these, 12 patients started CPAP therapy and formed the third group. RESULTS The mean follow-up period was 46.4 ± 14.3 months. Event-free survival was lowest in the untreated OSAHS patients (log rank test 6.732, p = 0.035). In the non-adjusted regression model, OSAHS was also associated with a higher risk of cardiovascular events (OR = 8.557, 95% CI 1.142-64.131, p = 0.037). OSAHS patients demonstrated higher rates of hospitalization compared to the control group without SBD (OR 2.750, 95%CI 1.100-6.873, p = 0.04). CONCLUSIONS OSAHS hypertensive patients, and in particular, according to our model, patients with severe OSAHS (AHI ≥ 30/h), are at higher risk of fatal and non-fatal cardiovascular events. Moreover, untreated OSAHS patients demonstrate higher rates of hospitalization caused by the onset or deterioration of cardiovascular disease.
Collapse
Affiliation(s)
| | - Yurii V. Sviryaev
- Almazov Federal Heart, Blood and Endocrinology Centre, Saint-Petersburg, Russia
| | - Nadezhda E. Zvartau
- Almazov Federal Heart, Blood and Endocrinology Centre, Saint-Petersburg, Russia
| | | | | |
Collapse
|
8
|
Eroshina EV, Kalinkin AL, Sidorenko BA. [The use of screening methods in diagnosis of disturbances of respiration during sleep in patients with cardiac pathology]. Kardiologiia 2011; 51:27-36. [PMID: 21649593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Disturbances of respiration during sleep especially those of obstructive character are sufficiently widespread phenomena. In addition to worsening of the quality of sleep itself they facilitate formation and development of concomitant pathology of cardiovascular system, endocrine system, cognitive sphere. This results in lowering of quality of life and its duration. At present standard method of diagnosis of disturbances of respiration during sleep is polysomnographical examination. At the same time more accessible screening methods are also actively used with the aim of detection of subjects with high probability of respiratory disturbances during sleep. Among them cardiorespiratory monitoring, nocturnal pulsoximetry, registration of oro-nasal flow during sleep, are questionnaires most widely-spread.
Collapse
|
9
|
Zvartau NE, Conrady AO, Sviryaev YV, Rotari OP, Merkulova NK, Kalinkin AL, Shlyakhto EV, Bagrov AY. Marinobufagenin in hypertensive patients with obstructive sleep apnea. Cell Mol Biol (Noisy-le-grand) 2006; 52:24-7. [PMID: 17535732] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2006] [Accepted: 10/30/2006] [Indexed: 05/15/2023]
Abstract
Although obstructive sleep apnea (OSA) is an independent risk factor for hypertension, the underlying mechanisms are not clearly understood. Apnea and hypopnea episodes during sleep lead to sympathoactivation, decrease plasma pH, and predispose to sodium and volume retention. We hypothesized that, the latter could stimulate digitalis-like natriuretic/vasopressor hormones, endogenous ouabain (EO) and marinobufagenin (MBG). Overnight polysomnography (Embletta) and 24 hrs blood pressure monitoring (SpaceLab 90207) was conducted in 52 consecutive patients with OSA (51 +/- 8 years; 40 males, 12 females) and in 48 age-matched hypertensive subjects without OSA. According to the polysomnography data, 17 patients had a mild degree of OSA (apnea/hypopnea index (AHI) 5-15), 17 patients-moderate (AHI 15-30) and 18 -severe OSA (AHI >30). Levels of MBG excretion co-varied with OSA severity (0.5 +/- 0.1, 0.9 +/- 0.04 and 1.2 +/- 0.06 nmoles per 24 hrs, respectively), while excretion of EO did not differ in patients with different degrees of OSA severity. Our observations suggest that MBG may be involved in the pathogenesis of hypertension in OSA, and may be a marker of OSA severity.
Collapse
Affiliation(s)
- N E Zvartau
- Almazov Research Institute of Cardiology, Saint-Petersburg, Russia
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Litvin AI, Pevzner AV, Mazygula EP, Nesterenko LI, Galiavi RA, Galitsin PV, Kalinkin AL, Chazova IE, Golitsyn SP. [Cardiac arrest in a patient with obstructive sleep apnea during sleep]. TERAPEVT ARKH 2004; 76:89-91. [PMID: 15332586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
|
11
|
Sheludchenko TP, Lopatin AS, Kalinkin AL, Barkova AM. [Polysomnographic results of surgical treatment of obstructive apnea syndrome]. Vestn Otorinolaringol 2003:28-32. [PMID: 13677020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/23/2023]
Abstract
The study was made of 20 patients suffering from mild, moderate and severe snore and obstructive sleep apnea. The patients were treated surgically but because their upper respiratory pathology varied the intervention consisted of several one-stage operations in the nasal cavity, nasopharynx and oropharynx. To remove nasal obstruction, operations on the nasal septum and/or turbinated bones were made. Pharyngeal surgery varied from uvulotomy and volumetric reduction of the soft palate thickness to uvulopalatopharyngoplasty with tonsillectomy. The results of polysomnography performed after surgical intervention confirmed efficacy of surgical treatment. A more than 2-fold decrease of the index apnea/hypopnea was registered in 75% patients with moderate and in 83% patients with a severe form of obstructive sleep apnea syndrome.
Collapse
|
12
|
Eroshina VA, Gasilin VS, Buzunov RV, Kalinkin AL. [Efficiency of intraoral applicator UPLH-01 in snore and obstructive sleep apnea]. Klin Med (Mosk) 2001; 79:44-7. [PMID: 11496740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
Tolerance, subjective and objective effectiveness of domestic intraoral applicator UPLH-01 were studied in the treatment of snoring and obstructive sleep apnea (OSA). In 44 patients with uncomplicated snoring the above parameters were assessed using questionnaire, in 20 patients with uncomplicated snoring and OSA paired polysomnographic investigations were made. Tolerance of the treatment was 50%. Subjective positive effect was registered in 65% of the patients. The applicator was found effective in the majority of patients with uncomplicated snoring. In mild and moderate OSA the applicator was effective only in a few cases. In severe OSA no effect was found. Patients with chronic disorders of nasal breathing exhibited deterioration of respiration and blood saturation with oxygen. Thus nasal obstruction is a contraindication to applicator use.
Collapse
|